Is LHX a buy, hold, or sell?
LHX carries a valuation grade of Buy. The trailing P/E of 32.9 sits 50% above the Industrials sector median of 22.0x — a premium that demands sustained earnings delivery. Our discounted cash flow model produces an intrinsic range of $266–$409 — implying a +11% margin of safety at the current price of $303.00. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 12% beat rate on recent quarters, earnings predictability has been mixed. Analyst estimate revisions are trending upward.
What are LHX's key risk factors?
With a beta of 0.75, LHX exhibits a defensive risk profile relative to the broad market. The 95th-percentile CVaR of -15.6% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 1.6% of total portfolio loss in the worst 5% of months. Net margins stand at 10.4%. The balance sheet is conservatively leveraged at 35% debt-to-equity.
At 0.00, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied volatility of 8.0% is below realized volatility of 24.6%, potentially making options relatively cheap. Insiders have been net sellers to the tune of $49.9M recently. While routine dispositions are common, the magnitude bears watching. Short interest is low at 1.5% of float, suggesting limited bearish conviction.
How does LHX fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — LHX carries a beta of 0.75, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, LHX shows the strongest co-movement with NOC (0.65), RTX (0.60), GD (0.59). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The LHX analysis here is a single node in that larger structure.
For the full transatlantic conviction hierarchy — including LHX's position sizing, conviction rating, and upside/risk case in the 2026 defence supercycle — see: Defence Spending 2026: The Transatlantic Allocation Case →
